Biopsy report explained

Cribriform Pattern and — Intraductal Carcinoma

Your biopsy report may use words like 'cribriform' or 'intraductal carcinoma' without explaining what they mean. Both are growth patterns that carry extra weight in the discussion about surveillance — and both are worth asking your urologist or oncologist about directly.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

A pattern within grade 4 — Cribriform sits inside Gleason grade 4, but ISUP treats it as a more adverse form of grade 4 than other patterns in the same grade.
IDC-P is outside the grading system — Intraductal carcinoma is not given a Gleason grade, but ISUP asks pathologists to report it separately because it matters clinically.
The score alone may not tell the full story — Two reports with identical Gleason scores can carry very different implications if one contains cribriform pattern.
This changes the surveillance conversation — Many active surveillance programmes list these features as reasons to discuss active treatment rather than continued observation.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Cribriform pattern and intraductal carcinoma (IDC-P) are growth patterns a pathologist identifies in prostate biopsy tissue. Both are adverse features that carry more clinical weight than the Gleason score alone conveys. Their presence on a report often changes the discussion about active surveillance, even when the overall grade looks similar to other patients.

What do these terms on the biopsy report actually mean?

Cribriform pattern: A sieve-like arrangement of cancer cells, where the cells form arch-like structures with open spaces between them. It is classified as Gleason grade 4, but ISUP guidance recognises it as more aggressive than other forms of grade 4 — such as fused glands — in the same scoring band.
Intraductal carcinoma of the prostate (IDC-P): Cancer cells that have spread into and filled the existing ducts and glands of the prostate. It is not assigned a Gleason grade, but ISUP guidance requires it to be reported separately because it is frequently found alongside high-grade invasive cancer and signals a more aggressive tumour environment.
Adverse pathological feature: A finding on a biopsy report that signals more aggressive tumour behaviour than the Gleason score alone captures. Both cribriform pattern and IDC-P fall into this category under ISUP and NCCN guidance.
ISUP: The International Society of Urological Pathology — the body that sets the international standards pathologists follow when grading prostate biopsies. Their 2019 consensus update specifically required cribriform pattern and IDC-P to be named and reported on every prostate biopsy.

What to look for on your biopsy report

Check whether the word 'cribriform' appears under any core's grade description
Check whether 'intraductal carcinoma' or 'IDC-P' appears as a separate line item
Note how many cores were taken and how many contain grade 4 or higher tissue
Note whether a percentage of cribriform within grade 4 is stated — some reports include this
Bring the printed report to your appointment; verbal summaries sometimes omit these details

Does finding cribriform or IDC-P rule out active surveillance?

It does not automatically rule it out, but it does change the conversation. Your urologist or oncologist makes the decision based on the full picture — the biopsy report, your MRI, your PSA trend, and your preferences.

ISUP and NCCN guidelines list both cribriform pattern and IDC-P as adverse features that should be factored into the surveillance decision. Many established surveillance programmes treat their presence as a reason to discuss active treatment rather than observation.

If surveillance has already been raised as an option for you, the specific question to bring to your next appointment is whether your team's protocol treats cribriform or IDC-P as an exclusion criterion. The answer depends on which protocol they use.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

How are cribriform pattern and intraductal carcinoma different from each other?

	Cribriform pattern	Intraductal carcinoma (IDC-P)
What it is	A sieve-like growth arrangement of invasive cancer cells within the prostate tissue	Cancer cells filling and expanding the existing ducts and glands of the prostate
Gleason grade	Assigned as Gleason grade 4	Not assigned a Gleason grade — sits outside the grading system
How it appears on the report	Within the Gleason score breakdown; sometimes with a stated percentage of grade 4 that is cribriform	As a separate line item alongside the Gleason grade
What it signals	More aggressive behaviour than other grade 4 patterns such as fused glands	Frequently found alongside high-grade invasive cancer; signals a more aggressive tumour environment
Effect on surveillance	Listed as an adverse feature in ISUP and NCCN guidance; prompts review of surveillance eligibility	Listed as an adverse feature; ISUP guidance recommends it be considered in the surveillance decision

Did you know?

ISUP updated its grading guidelines in 2019 to require that cribriform pattern and intraductal carcinoma be named and reported separately on every prostate biopsy.

Before that update, these features were sometimes absorbed into the Gleason grade without being named — which means an older biopsy report may not mention them even if the pattern was present in the original slides.

Source: ISUP Consensus Conference 2019: Modified Gleason Grading System for Prostate Cancer

Questions this report finding raises

My Gleason score is 3+4. Does cribriform pattern change the score?

It does not change the arithmetic. A 3+4 report with cribriform pattern is still scored as 3+4. What changes is how that score is interpreted. ISUP guidance notes that cribriform grade 4 carries more clinical weight than non-cribriform grade 4, which means two patients with identical scores may receive different advice if one has cribriform pattern and the other does not. The score is a starting point; the pattern description adds to the picture.

Is IDC-P the same as having a higher Gleason grade?

No. Intraductal carcinoma is not assigned a Gleason grade at all — it sits outside the grading system entirely. But it is not a neutral finding. ISUP guidance describes IDC-P as a marker that frequently accompanies high-grade invasive cancer. Finding it in a biopsy core, even in a core that does not contain invasive carcinoma, is considered clinically significant and should be discussed with your treating team.

Can a second pathology opinion change what the report says?

It can. Identifying cribriform pattern and IDC-P requires experienced interpretation, and the distinction between cribriform and other forms of grade 4 involves pathological judgment. A review by a specialist uropathologist — at a centre with dedicated prostate pathology expertise — is a standard step when these features appear. Your urologist can request that the original slides be sent for review. This is not an unusual or confrontational request; it is common practice before major treatment decisions.

What does 'percentage cribriform' mean if it appears on the report?

Some reports now state what proportion of the grade 4 tissue is cribriform. Research published through ISUP suggests that a higher cribriform proportion is associated with more aggressive tumour behaviour than a small amount. There is no universally agreed threshold that triggers a specific management change on its own — your urologist interprets the percentage alongside the total amount of grade 4 across all cores, your MRI findings, and your PSA trend.

Will I need additional imaging because of this finding?

Multiparametric MRI of the prostate and, in some cases, PSMA PET-CT are used to assess the extent of disease after an adverse biopsy finding. Whether additional imaging is recommended depends on what imaging you have already had, your PSA level, and the full biopsy report. Raise this directly with your urologist at your next appointment, with the printed biopsy report in hand, so the conversation is specific to your results.

Explore 114 more Waiting For and Understanding Your Report topics

Gleason & Prostate Biopsy Reporting

Cytology Reporting Systems

Grade, Differentiation & Mitotic Index

Margins, LVI and PNI

Reading Your Histopathology Report

Staging on a Biopsy Report

Waiting for Results

All Waiting For and Understanding Your Report →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

What exactly is cribriform pattern on a prostate biopsy?

Cribriform pattern describes a sieve-like arrangement of cancer cells — they form arch-like structures with open spaces between them, rather than growing as isolated units or simple fused glands. It falls within Gleason grade 4, but ISUP guidance recognises it as a more aggressive form of grade 4 than other patterns in the same grade. Your pathologist identifies it from the biopsy tissue under a microscope and records it in the report alongside the standard Gleason grading.

Does cribriform pattern mean I definitely cannot have active surveillance?

Not definitively, but it is one of the strongest reasons to review that option carefully with your team. NCCN and ISUP guidance list cribriform pattern as an adverse feature that should directly inform the surveillance decision. Many active surveillance protocols treat its presence as a reason to discuss active treatment rather than continued observation. Whether it changes your specific plan depends on the protocol your team follows and the rest of your clinical picture — ask your urologist whether their programme treats it as an exclusion criterion.

What is intraductal carcinoma and how is it different from ordinary prostate cancer?

Intraductal carcinoma (IDC-P) is not a separate cancer type — it is a pattern in which cancer cells have spread into and filled the existing ducts and glands of the prostate rather than forming new invasive structures. It is not given a Gleason grade, but it is reported separately because it frequently appears alongside high-grade disease and signals a more aggressive tumour environment. Even when IDC-P appears in a core without associated invasive carcinoma, it is treated as a clinically significant finding.

Should I ask for a second pathology opinion on the biopsy?

It is a reasonable question to raise, and your urologist can arrange it. Identifying cribriform pattern and IDC-P requires experienced judgment, and specialist uropathologists at larger centres review these findings regularly. A second opinion does not mean the first was wrong — it means you want certainty before a major treatment decision. Ask your urologist whether the original slides can be sent to a specialist uropathology centre for review. This is a standard practice and a sensible step when these features appear.

My report mentions cribriform in only one core out of twelve. Does that still matter?

Yes, it can. ISUP guidance does not set a minimum number of positive cores for cribriform to be considered an adverse feature — its presence anywhere in the biopsy is reported as significant. How much weight your treating team gives it depends on the rest of the report: the total amount of grade 4 across all cores, what MRI shows, and your PSA trend. Bring the full core-by-core breakdown to your appointment so the discussion can be specific.

What questions should I bring to my next appointment?

Ask three things: whether cribriform pattern or IDC-P was found in your biopsy and in how many cores; whether the protocol your team uses for surveillance treats either feature as an exclusion criterion; and if so, what the recommended next step is and what it is intended to achieve. Writing the answers down, or asking for a printed summary, helps — these conversations are difficult to retain in full when you are anxious and the information is unfamiliar.

Full index